Optimal induction and post-remission therapy for acute myeloid leukemia.

about

Optimal induction and post-remission therapy for acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q40817111

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Optimal induction and post-remission therapy for acute myeloid leukemia.

@en

type

Item

label

Optimal induction and post-remission therapy for acute myeloid leukemia.

@en

prefLabel

Optimal induction and post-remission therapy for acute myeloid leukemia.

@en

P1476

Optimal induction and post-remission therapy for acute myeloid leukemia.

@en

P2093

A K Burnett

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

High-dose daunorubicin in older patients with acute myeloid leukemia.

Anthracycline dose intensification in acute myeloid leukemia.

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

P2888

leusup.2012.10

P304

S14-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEUSUP.2012.10

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027000760

http://www.w3.org/2001/XMLSchema#string

P698

27175233

http://www.w3.org/2001/XMLSchema#string

P932

4851191

http://www.w3.org/2001/XMLSchema#string